Core Insights - Fagron has completed the acquisition of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder in California, enhancing its position in the health and wellness segment [1][2] - The acquisition is valued at approximately $41.5 million, with UCP generating annual revenues of around $25 million and an EBITDA margin lower than Fagron's existing group margin [3] - Fagron aims to realize synergies from the integration of UCP over the next 18 to 24 months, as part of its strategy to build a nationwide platform in the United States [3][4] Company Strategy - The acquisition of UCP complements Fagron's existing operations, particularly with Anazao, and strengthens its footprint in California, a highly regulated healthcare market [2][4] - Fagron has executed fourteen acquisitions across various regions recently, indicating a strategy of selective expansion and vertical integration [3][5] - The company remains focused on execution and integration of acquired businesses to build a larger, higher-quality compounding platform [5] Financial Outlook - Fagron's financial calendar includes key dates for full-year results, trading updates, and the annual general meeting, with the next full-year results scheduled for February 12, 2026 [5]